All In Biotech

Drug Trial Radar · NCT02837237

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

A Phase 1, Open-Label Study in Hemodialysis and Non-Hemodialysis Patients With Severe Chronic Kidney Disease to Evaluate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration

Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

11

Actual

Start

Jul 13, 2016

Primary completion

Dec 20, 2016

Study completion Jun 30, 2017

Sponsor

Lead sponsor
KBP BiosciencesIndustry
Sponsor type
Industry
First posted
Jul 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study explores the use of KBP-5074 in patients with advanced stages of Chronic Kidney Disease (CKD) (including patients with severe renal impairment and those on hemodialysis \[HD\]) and to assess the safety, tolerability, and pharmacokinetics (PK) of single doses of KBP-5074 in male and female patients with severe CKD (defined as estimated glomerular filtration rate \[eGFR\] ≥15 mL/min/1.73 m2 and ≤29 mL/min/1.73 m2, based on the Modification of Diet in Renal Disease \[MDRD\] equation) and a subset of patients requiring HD.

Conditions

  • Chronic Kidney Disease

Interventions

  • KBP-5074Drug

    In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours. In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse EventsTime frame: 312 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • KBP Biosciences USA Inc

    Princeton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.